Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib [1]

Leukemia

Volumn 19, Issue 1, 2005, Pages 132-134

  Piazza, R G ^a,b   Magistroni, V ^a   Gasser, M ^c   Andreoni, F ^a   Galietta, A ^a   Scapozza, L ^c   Gambacorti Passerini, Carlo ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; OROSOMUCOID; PROTEIN TYROSINE KINASE; RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BLAST CELL CRISIS; CELL LINE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONCENTRATION RESPONSE; ENTROPY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; IC 50; IN VITRO STUDY; LETTER; LEUKEMIA CELL; LEUKEMIA RELAPSE; MISSENSE MUTATION; MORTALITY; MOUSE STRAIN; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME;

EID: 11944263830     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403453     Document Type: Letter

References (8)

1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
2. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing Imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664-672.
3. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-843.
4. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to Imatinib. Hematol J 2004; 5: 55-60.
5. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to Imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85.
6. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to Imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
7. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9: 625-632.
8. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.